A serotonin gene variant influenced brain response to cannabis treatment in adolescents
A serotonin receptor gene polymorphism (rs6311) was associated with different brain activation patterns in adolescents after psychosocial treatment for cannabis use disorders.
Quick Facts
What This Study Found
This preliminary study examined whether genetic variations in the serotonin system moderated brain responses to psychosocial treatment for adolescent cannabis use disorders. Two serotonin gene polymorphisms were tested: a receptor variant (rs6311) and a transporter variant (rs2020936).
The original hypotheses were not supported. However, the rs6311 C allele was significantly associated with brain activation in the medial frontal gyrus and precuneus after treatment, suggesting this serotonin receptor variant plays a role in how adolescent brains respond to cannabis treatment.
These regions are involved in self-reflection and internal processing, suggesting the genetic variant may influence treatment-related changes in self-awareness and motivation.
Key Numbers
Two polymorphisms tested: rs6311 (serotonin receptor) and rs2020936 (transporter). rs6311 C allele associated with activation in medial frontal gyrus and precuneus.
How They Did This
fMRI study of adolescents with cannabis use disorders following psychosocial treatment. Participants were genotyped for serotonin receptor (rs6311) and transporter (rs2020936) polymorphisms. Brain activation patterns were compared across genotypes.
Why This Research Matters
If genetic variants predict treatment response, future cannabis treatment could be personalized based on individual biology. The serotonin system connection also explains why anxiety and depression commonly co-occur with cannabis use disorders.
The Bigger Picture
Pharmacogenomics in addiction treatment is in its early stages. This study provided initial evidence that genetic factors might influence not just susceptibility to cannabis problems but also response to treatment.
What This Study Doesn't Tell Us
Preliminary study with small sample size. Original hypotheses were not supported. Single gene variant findings require replication. Could not determine whether the brain differences predicted actual treatment outcomes.
Questions This Raises
- ?Does the rs6311 variant predict long-term treatment success?
- ?Would medications targeting the serotonin system enhance treatment for cannabis use disorders in carriers?
- ?Can pharmacogenomic testing guide treatment selection?
Trust & Context
- Key Stat:
- Serotonin receptor gene variant linked to treatment-related brain changes
- Evidence Grade:
- Preliminary fMRI pharmacogenomic study. Exploratory analysis after original hypotheses were unsupported. Requires replication in larger samples.
- Study Age:
- Published in 2012. Pharmacogenomics in addiction treatment remains an emerging field.
- Original Title:
- A preliminary examination of how serotonergic polymorphisms influence brain response following an adolescent cannabis intervention.
- Published In:
- Psychiatry research, 204(2-3), 112-6 (2012)
- Authors:
- Feldstein Ewing, Sarah W(4), Mead, Hilary K, Yezhuvath, Uma(2), Dewitt, Sam, Hutchison, Kent E, Filbey, Francesca M
- Database ID:
- RTHC-00559
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Could genetic testing improve cannabis treatment?
This early study found one serotonin gene variant influenced brain responses to treatment. While promising conceptually, the finding is preliminary and genetic testing is not yet practical for guiding cannabis treatment decisions.
Why would serotonin genes matter for cannabis treatment?
Depression and anxiety commonly co-occur with cannabis use disorders, and the serotonin system is central to mood regulation. Genetic variations in serotonin function may influence how well someone responds to treatment by affecting motivation, self-reflection, and emotional processing.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-00559APA
Feldstein Ewing, Sarah W; Mead, Hilary K; Yezhuvath, Uma; Dewitt, Sam; Hutchison, Kent E; Filbey, Francesca M. (2012). A preliminary examination of how serotonergic polymorphisms influence brain response following an adolescent cannabis intervention.. Psychiatry research, 204(2-3), 112-6. https://doi.org/10.1016/j.pscychresns.2012.10.011
MLA
Feldstein Ewing, Sarah W, et al. "A preliminary examination of how serotonergic polymorphisms influence brain response following an adolescent cannabis intervention.." Psychiatry research, 2012. https://doi.org/10.1016/j.pscychresns.2012.10.011
RethinkTHC
RethinkTHC Research Database. "A preliminary examination of how serotonergic polymorphisms ..." RTHC-00559. Retrieved from https://rethinkthc.com/research/feldstein-2012-a-preliminary-examination-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.